CD274 and non-small cell lung carcinoma: Our analysis demonstrated that, for the three categories of PD-L1 expression status populations, whether the PAP was available or not, atezolizumab as first-line treatment for metastatic NSCLC was unlikely to be cost-effective due to the unfavorable ICER when the WTP threshold was $30,828/QALY regardless of PD-L1 expression status, and the results were robust as shown by one-way sensitivity and probabilistic sensitivity analyses.